EDITORIAL GOVERNANCE & MEDICAL REVIEW
-
✓
Content Author: Ms. Hannah Matthews (B.Sc. - Biochemistry)
-
✓
Medically Reviewed By: Dr. N. Kumar, DM, Member of the International Society for Stem Cell Research (ISSCR).
-
✓
State Medical Council Registration No.: Medical Registration Verified | Member, Indian Academy of Neurology
-
✓
Expert Scientific Reviewer: Dr. Harinath P, PhD (Stem Cell Biology & Regenerative Immunology)
-
✓
Clinical Governance Protocol:
SOP-NKC-04(Investigational Cellular Protocol)
Condition Context & Investigational Scope
Clinical classification, underlying pathophysiology, and biological cellular rationale in India
Clinical Classification & Regulatory Status:
Natural Killer (NK) cell therapy is an experimental cellular immunotherapy, distinct from standard chemotherapy and bone marrow transplants.
Pathophysiology & Disease Context:
Mechanism of Action: NK cells are specialized lymphocytes of the innate immune system capable of identifying and destroying malignant cells without prior human leukocyte antigen (HLA) sensitization, releasing perforin and granzymes, and secreting anti-tumor cytokines (such as IFN-γ).
Biological Rationale & Paracrine Action:
Investigates the immunomodulatory and trophic paracrine potential of clinical-grade mesenchymal stem cells to support tissue homeostasis, cellular repair, and inflammatory moderation.
Candidate Eligibility & Diagnostic Pre-Screening
Comprehensive inclusion markers, mandatory diagnostics, and safety exclusion parameters
Target Patient Profile:
Adult and pediatric patients with histologically confirmed advanced solid tumors or relapsed/refractory hematologic malignancies participating in an active clinical trial protocol.
Mandatory Pre-Procedure Diagnostics:
Pre-Screening Requirements: Recent PET-CT or contrast CT restaging, biopsy pathology/immunohistochemistry (IHC) reports, baseline organ function panels (LVEF ≥ 50% on 2D-ECHO, liver and renal profiles), and absolute lymphocyte count.
Strict Safety Exclusion Parameters:
Rapidly progressing spinal cord compression, severe active autoimmune disease requiring heavy systemic immunosuppression, active uncontrolled infection, or end-stage organ failure.
Triage Protocol & Multi-Specialty Clearance:
Pre-travel multi-disciplinary medical board evaluation and baseline scan review prior to issuing medical visa invitation clearance.
Potential Functional Goals & Documented Risks
Reported supportive clinical goals alongside complete procedural and biological risk transparency
Reported Functional Goals (Supportive & Variable):
- Immune Activation: Increased circulating cytotoxic lymphocyte counts and reduction in immunosuppressive regulatory T cells.
- Tumor Control: Exploratory monitoring of stable disease (RECIST criteria) and partial metabolic responses when evaluated alongside standard systemic therapies.
- Quality of Life: Potential reductions in fatigue and improvements in functional performance scores (ECOG/KPS).
Documented Procedural Risks & Limits:
- Transient infusion reactions, low-grade pyrexia (fever), chills, or localized vein discomfort (resolving within 24–48 hours).
- Risk of mild, low-grade cytokine release syndrome (CRS) or immune-mediated transient transaminitis.
- No Guaranteed Response: Tumor microenvironments can suppress NK activity; cellular infusion does not guarantee remission or disease regression.
Why Undergo Treatment at Our Medical Center in India?
World-class tertiary healthcare infrastructure, cGMP certified cleanrooms, and compassionate patient-centered care
Accreditation
Hospital-based clinical research conducted in tertiary oncology centers accredited by NABH and JCI.
cGMP Cleanroom Purity
Cell isolation, characterization, and expansion executed in CDSCO-compliant cleanrooms adhering to international Good Manufacturing Practices.
Multidisciplinary Tumor Board
Collaborative oversight by medical oncologists, clinical hematologists, cellular immunologists, and intensive care specialists.
Transparent Trial Governance
Supervised by a registered Institutional Ethics Committee (IEC); patients are enrolled strictly under transparent clinical protocols.
Treatment Costs & Package Inclusions
Transparent international pricing with comprehensive hospital, procedural, and travel inclusions
(comprehensive inpatient package covering targeted cellular therapy, hospital stays, and follow-up).
(Administered under strict cGMP cleanroom standards and multidisciplinary physician oversight).
| Country / Region | Typical Package Range | Waiting Period | Clinical Accreditation |
|---|---|---|---|
| India (Our Partner Centers) | Starting from $4,000 USD | 1 – 2 Weeks | JCI / NABH Accredited |
| United States | $28,000 – $55,000 USD | 3 – 6 Months | Clinical Trial Gated |
| Germany & Switzerland | $25,000 – $48,000 USD | 2 – 4 Months | Private Specialty Only |
| Panama / Mexico | $18,000 – $35,000 USD | 2 – 4 Weeks | Variable Regional |
Dedicated Support for International Patients & Families
End-to-end medical concierge care ensuring a safe, stress-free international treatment journey
Remote Case Triage
Video teleconsultation with treating oncologists to evaluate whether trial protocols offer valid adjunctive utility.
Medical Visa Documentation
Official Government of India Medical Visa (MED) and Attendant (MED-X) invitation letters.
Dedicated International Desk
Multilingual patient coordinator managing hospital appointments, document translations, and local logistics.
Structured Long-Term Follow-Up
Telehealth checkpoints at Months 1, 3, 6, and 12, coordinating scan evaluations directly with your primary home oncologist.
Travel, Accommodation & Local Logistics
Planning your medical journey to New Delhi, Mumbai, or Bangalore with complete peace of mind
Sanitized Transfers
Dedicated, private airport pick-up and drop-off to safeguard immunocompromised cancer patients from crowded transit.
Inpatient Accommodations
Private hospital suites featuring HEPA filtration, private attendant bedding, barrier-free access, and 24/7 oncology nursing.
Outpatient Recovery Stays
Inspected partner serviced apartments within 3 km of the hospital campus for families awaiting laboratory expansion cycles.
Clinical Protocol & In-Hospital Schedule
Structured clinical workflow during your stay in India (Stay Duration: 4 to 5 Days):
Arrival, Admission & Baseline Diagnostics
Airport reception, hospital check-in, primary physician review, comprehensive blood panels, vital organ assessment, and baseline imaging scans.
Pre-Procedure Preparation & Multi-Specialty Clearance
Review of diagnostic profiles by the clinical committee, premedication, and certified cleanroom preparation of cellular biologics.
Targeted Cellular Administration
Delivery of clinical-grade cellular biologics under strict aseptic conditions in an advanced surgical/interventional procedure suite.
Post-Procedure Observation, Supportive Care & Discharge
Vital sign stability monitoring, supportive therapy, discharge counseling, and fit-to-fly clearance certification.
Clinical Safety Profile & Post-Treatment Monitoring
Rigorous clinical governance, low adverse event rates, and structured long-term remote follow-up
Anticipated Transient Responses
- Mild transient low-grade fever resolving within 12 to 24 hours.
- Mild localized injection-site soreness or temporary tenderness.
- Transient procedural fatigue responsive to oral hydration and rest.
Quality & Cleanroom Safeguards
- Certified cGMP cleanroom facilities with ISO-Class 5 / Class 10,000 air handling.
- Flow cytometry viability testing (>90% cell viability confirmed).
- Rigorous sterility screening for endotoxins, mycoplasma, and viral pathogens.
Structured 12-Month Remote Follow-Up Care
Following discharge, our medical team conducts scheduled teleconsultations at 1, 3, 6, and 12 months to review functional progress, track laboratory biomarkers, and coordinate directly with your local physician.
Frequently Asked Questions
Evidence-based answers to key clinical, safety, cost, and travel inquiries regarding Cancer (Natural Killer Cell Immunotherapy)
Peer-Reviewed Clinical Trial References & Registry Citations
Published scientific trials, systematic reviews, and official registry citations validating cellular safety and therapeutic mechanisms
Cord Blood-Derived Engineered CAR-NK Cells for Lymphoid Tumors
Liu, E., Marin, D., Banerjee, P., Macapinlac, H. A., Thompson, P., Basar, R., ... & Rezvani, K. (2020). Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. New England Journal of Medicine, 382(6), 545–553. Clinical Significance: Demonstrated a 73% objective response rate (8 of 11 patients) with allogeneic cord blood–derived CD19 CAR-NK cells armed with IL-15 in relapsed/refractory non-Hodgkin lymphoma and CLL, with no observed graft-versus-host disease (GvHD), cytokine release syndrome (CRS), or neurotoxicity.
Allogeneic Haploidentical NK Cell Infusions for Poor-Prognosis AML
Miller, J. S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., ... & Weisdorf, D. J. (2005). Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood, 105(8), 3051–3057. Clinical Significance: Foundational phase I/II clinical trial showing that high-dose cyclophosphamide and fludarabine lymphodepletion induces endogenous IL-15, enables in vivo donor NK cell expansion, and achieved complete hematologic remissions in refractory acute myeloid leukemia (AML) patients without causing GvHD.
Haploidentical NK Cells for Pediatric AML Consolidation
Rubnitz, J. E., Inaba, H., Ribeiro, R. C., Pounds, S., Rooney, B., Bell, T., ... & Leung, W. (2010). NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. Journal of Clinical Oncology, 28(6), 955–959. Clinical Significance: Validated the feasibility and safety of killer immunoglobulin-like receptor (KIR)–HLA-mismatched donor NK cell infusions in pediatric AML patients in complete remission, showing successful alloreactive NK engraftment without major toxicity.
Allogeneic NK Cell Therapy for Advanced Recurrent Solid Tumors
Geller, M. A., Cooley, S., Judson, P. L., Ghebre, R., Carson, L. F., Argenta, P. A., ... & Miller, J. S. (2011). A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy, 13(1), 98–107. Clinical Significance: Evaluated lymphodepleting chemotherapy followed by allogeneic haploidentical NK cell infusions in recurrent ovarian and breast cancer, providing important safety data while illustrating the biological challenges of NK cell trafficking and immunosuppression in solid tumor microenvironments. Clinical Trials Registry - India (CTRI) Citations & Search Protocol Registry Host: Clinical Trials Registry - India (CTRI) (ICMR–National Institute of Medical Statistics). Registry Compliance Mandate: In India, all clinical studies administering cellular immunotherapies (including autologous expanded NK cells, cord-blood NK cells, and cytokine-induced killer [CIK] cells) must be prospectively registered in the CTRI database following Central Drugs Standard Control Organisation (CDSCO) / Institutional Ethics Committee (IEC) review. Verification Parameter: Search terms such as "Natural Killer", "NK cell", or "Autologous Cytotoxic Lymphocytes" under the CTRI Trial Search to inspect ethics clearances, trial phases, and investigator affiliations for oncology protocols in India.
Statutory Notice & Mandatory Regulatory Disclosure:
In accordance with the National Guidelines for Stem Cell Research and directives from the National Medical Commission (NMC) and Central Drugs Standard Control Organisation (CDSCO), Natural Killer (NK) cell therapy is not an approved standard of care or definitive cure for cancer in India. It is an investigational immunotherapy offered strictly within ethics-committee-approved clinical research trials. Patients must never discontinue, delay, or substitute proven standard oncological interventions (such as surgery, systemic chemotherapy, radiotherapy, or approved targeted/checkpoint therapies) in favor of investigational cell therapies.\
In compliance with the National Guidelines for Stem Cell Research jointly formulated by ICMR and DBT, and directives from NMC, cellular therapies described on this website are investigational. Patients should never alter or stop prescribed baseline medications without consulting their primary physician.